Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus by Sebastian Dolff et al.
RESEARCH ARTICLE Open Access
Increased expression of costimulatory markers
CD134 and CD80 on interleukin-17 producing
T cells in patients with systemic lupus
erythematosus
Sebastian Dolff1,2†, Daniel Quandt1†, Benjamin Wilde1, Thorsten Feldkamp1, Fan Hua1, Xin Cai1, Christof Specker3,
Andreas Kribben1, Cees GM Kallenberg2, Oliver Witzke1*
Abstract
Introduction: There is growing evidence that interleukin 17 (IL-17) producing T cells are involved in the
pathogenesis of systemic lupus erythematosus (SLE). Previous studies showed that increased percentages of T-cell
subsets expressing the costimulatory molecules CD80 and CD134 are associated with disease activity and renal
involvement in SLE. The aim of this study was to investigate the distribution and phenotypical characteristics of IL-
17 producing T-cells in SLE, in particular in patients with lupus nephritis, with emphasis on the expression of CD80
and CD134.
Methods: Thirty-four patients (3 male, 31 female, mean age 41 ± 15 years) fulfilling at least four of the American
College of Rheumatology (ACR) revised criteria for the diagnosis of SLE and 24 healthy controls were enrolled.
T-cells from the peripheral blood were analysed by fluorescence activated cell sorting (FACS) for their expression
levels of CD80, CD134 and CCR6. In vitro stimulated CD3+IL17+ cells were also investigated for the expression of
these costimulatory markers. Finally, renal biopsies from SLE patients were evaluated for the presence of CD134
expressing T-cells.
Results: Percentages of IL-17 expressing T-cells were significantly increased in patients with active disease as
compared to healthy controls (1.46 ± 0.58% versus 0.93 ± 0.30%, P = 0.007). The percentage of IL-17 producing
T-cells was correlated with disease activity as assessed by systemic lupus erythematosus disease activity index
(SLEDAI) (r = 0.53, P = 0.003). In patients, most of the IL-17 producing T-cells were confined to the CCR6+ T-cell
subset (80 ± 13%). Expression of CD80 and CD134 on the IL-17 producing T-cell subset was higher in SLE than in
healthy controls (HC) (CD134: 71.78 ± 14.51% versus 51.45 ± 16.58%, P = 0.002; CD80: 25.5 ± 14.99% versus 14.99 ±
5.74%, P = 0.02). Also, patients with lupus nephritis expressed higher levels of CD134+ on CD3+IL-17+ cells as
compared to HC (72.69 ± 11.54% versus 51.45 ± 16.58%, P = 0.006). Furthermore, renal biopsies of lupus nephritis
patients showed infiltration of CD134+ T cells.
Conclusions: Percentages of IL-17 expressing T-cells correlate with disease activity. Further, these cells show
increased expression of costimulatory markers such as CD134 and CD80. The presence of CD134+ T-cells in renal
biopsies of lupus nephritis patients suggest that these cells migrate to the kidney and might contribute to
inflammatory processes through IL-17 secretion.
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Introduction
Systemic lupus erythematosus (SLE) is a multiorgan auto-
immune disease characterized by an imbalanced T cell
homeostasis with a shift towards activated effector T-cell
subsets. Two major subsets of CD4+ T helper cells, Th1
and Th2, have been shown to be involved in the pathogen-
esis of SLE. Th1 cells secrete interferon gamma (INF-g)
and are induced by IL-12, whereas Th2 cells secrete IL-4,
IL-5 and IL-13 and are induced by IL-4 [1,2].
More recently, another subset of cytokine producing
T-cells, so called Th17 cells producing the cytokine IL-
17, were described. IL-17 exerts its function through
recruiting neutrophils and monocytes, upregulating local
chemokine expression, facilitating T cell migration into
tissues, and inducing immune responses [3-6]. There is
increasing evidence that IL-17-producing T-cells play an
important role in various autoimmune diseases includ-
ing multiple sclerosis, psoriasis, rheumatoid arthritis,
inflammatory bowel disease, ANCA associated vasculitis
and systemic lupus erythematosus [7-11].
Recent studies demonstrated the importance of IL-17
produced by different T-cell subsets such as CD4+ T-
cells, CD8+ T cells, CD3+CD4-CD8- T-cells, and gδ T-
cells in human SLE [12,13]. Furthermore, Yang et al.
reported an association of IL17-producing T-cells and
clinical features as disease activity assessed by systemic
lupus erythematosus disease activity index (SLEDAI)
[14]. Studies investigating the role of IL-17-producing
T-cells in the pathogenesis of lupus nephritis (LN) are
rare. However, studies in mice support the idea that IL-
17 may contribute to renal disease, in particular lupus
nephritis [14-17]. Crispin et al. demonstrated infiltration
of IL-17+ double negative T-cell in kidneys of lupus
nephritis patients [12]. More recently, single-cell analysis
of laser-microdissected lupus nephritis sections showed
a skewing towards IL-17 [18]. Further evidence comes
from urine analysis in lupus nephritis patients where IL-
17 gene expression was inversely correlated with disease
activity [19]. These studies demonstrated the pivotal
role of IL-17 cells in the pathogenesis of lupus nephritis.
In humans an overwhelming amount of IL-17 cells
express the chemokine receptor CCR6 [20]. Therefore,
CCR6 might be a useful phenotypic marker for the ana-
lysis of IL-17 T-cells.
Previously, we reported an association of increased
levels of costimulatory markers on CD4+ cells with
lupus nephritis [21]. Especially, expression of CD134
was associated with disease activity and renal involve-
ment, but a functional analysis of these CD134 expres-
sing cells is still lacking. As a member of the tumour
necrosis factor (TNF) superfamily, CD134 (OX40) pro-
vides co-stimulatory signals upon ligation to the
CD134Ligand. Moreover, it is possible that CD134+
T cells infiltrate kidneys and cause inflammation after
ligation with CD134L which has been shown to be pre-
sent on glomerular endothelial cells in SLE patients
[15]. Thus, CD134 might be a pivotal surface marker to
enable effector cell migration towards the kidney. The
significance of CD134 for effector functions has been
shown by the observation that treatment with a stimula-
tory anti-CD134 antibody enhances T cell expansion
and differentiation to effector cells in mice [22,23]. This
stimulation, apparently, promotes the secretion of IFN-g
and the upregulation of various interleukin (IL)-recep-
tors which might lead subsequently to cytokine-
mediated kidney cell damage [24]. Remarkably,
increased percentages of CD134 expressing T-cells as
well as Th17 cells have been found amongst effector
cells in several autoimmune diseases such as Wegener’s
granulomatosis, rheumatoid arthritis and myasthenia
gravis [7,25-28].
To elucidate the role and phenotype of IL-17 produ-
cing effector T-cells in patients with systemic lupus
erythematosus, in particular with lupus nephritis, we
investigated their presence and phenotypic characteris-
tics in the present study. We analysed not only periph-
eral blood but also tissue from patients with lupus
nephritis. We tested the hypothesis that increased
expression of costimulatory molecules on these cells
may promote their infiltrations into the kidney due to
interaction with ligands on resident renal cells.
Materials and methods
Thirty-four patients (3 male, 31 female, mean age 41 ±
15 years) fulfilling at least four of the American College
of Rheumatology (ACR) revised criteria for the diagnosis
of SLE and 24 healthy controls (mean age 46 ± 14 years)
were enrolled in the study. Thirteen patients had lupus
nephritis (WHO Class II: two patients, Class III: one
patient, Class IV: five patients, Class V: four patients,
unclassified: two patients) while 22 patients had no clin-
ical evidence of lupus nephritis (absence of proteinuria
and/or glomerular hematuria). Clinical disease activity at
the time of measurement was assessed according to the
systemic lupus erythematosus disease activity index
(SLEDAI) (mean SLEDAI 4 ± 5). Patients with a SLE-
DAI ≥4 were defined as active; 19 active and 15 inactive
patients were included in the study. A total of 26
patients were treated with prednisone (mean 27 ± 91
mg/d), 8 patients did not receive prednisone, and 23
patients were on a constant dose of immunomodulating
drugs (azathioprin (n = 8), mycophenolate mofetil (n =
10), cyclosporin A (n = 2), hydroxychloroquin (n = 9),
leflunomide (n = 1), rituximab (n = 2)), 2 patients had
no medication at the time of the study. Thirteen
patients had been treated with cyclophosphamide (mean
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dose: 2,003 ± 4,193 mg) during their disease course.
Consecutive patients were included from the University
Hospital of Essen and the Medical Center Essen-Süd.
The study protocol was approved by the institutional
review board. All patients gave informed consent for
participation in this study.
Flow cytometry
Expression level of the surface molecules on lympho-
cytes was assessed by four-colour surface staining. Phy-
coerythrin (PE), fluorenscein isothiocyanate (FITC),
peridin chlorophyll protein (PerCP) and Allophycocya-
nin (APC)-labelled antibodies were used: CD3 (mouse
IgG1, PerCP), CD4 (mouse IgG1, PerCP), CD8 (mouse
IgG1 FITC), CCR6 (mouse igG1, FITC), CD134 (mouse
IgG1, PE), CD80 (mouse IgG1, PE, R&D Systems, Wies-
baden, Germany) and IL-17 (mouse IgG1, APC). All
antibodies were purchased from Becton Dickinson, Hei-
delberg, Germany, except for IL-17, which was pur-
chased from eBioscience, San Diego, CA, USA, and
CCR6 purchased from R&D Systems, Minneapolis, MN,
USA. Appropriate isotype controls (Becton Dickinson)
were used. Briefly, peripheral blood was stained with
labelled monoclonal antibodies for 20 minutes in the
dark at room temperature. The cell suspension was
incubated with lysis buffer for 15 minutes and prepared
as indicated. Analysis was performed with a fluorescence
activated cell sorter (FACS) Calibur™ from Becton
Dickinson.
Immunostaining for intracellular cytokines
Peripheral blood mononuclear cells (PBMCs) of patients
were separated by standard Ficoll-Paque density gradient
centrifugation. The cells were resuspended in RPMI
1640 medium (Gibco BRL, Karlsruhe, Germany) supple-
mented with 10% heat inactivated fetal calf serum (Bio-
chrom, Berlin, Germany). The cells were cultured in the
absence or presence of PMA (5 ng/ml) and Ionomycin
(1 μM) (Sigma-Aldrich, Seelze, Germany) for five hours.
Cytokine secretion was inhibited by Brefeldin A
(Ebioscience, Frankfurt, Germany). Then surface staining
was performed with CD3, CD134, CD80, CCR6 and
appropriate isotype controls. Cells were fixed and per-
meabilized by using a Cytofix/Cytoperm kit purchased
from Becton Dickinson. Finally, the samples were intra-
cellulary stained with IL-17 or an appropriate isotype
control.
Immunohistochemistry
Renal biopsies were provided by the Institute of Pathol-
ogy University Hospital of Essen. Specimens were fixed
in 10% neutral buffered formaline and paraffin-
embedded. Sections 5 μm thick were deparaffinized in
xylene and rehydrated in a series of ethanol with
different concentrations (100%, 95%, 70% and 50%).
Citrate buffer pH 6.0 (Zytomed, Berlin, Germany) was
applied for heat induced epitope retrieval, followed by
neutralization of endogenous peroxidase with 0.3%
H2O2. Primary antibodies (CD3 obtained from DCS,
Hamburg, Germany and CD134 obtained from Becton
Dickinson) and HRP-conjugated secondary antibodies
(Zytomed) were incubated on slides (each for 30 min-
utes) at room temperature. Washing with PBS was per-
formed after each incubation step. A DAB substrate Kit
(Zytomed) was used for visualization. Finally, the slides
were slightly counterstained with hematoxylin.
Immunofluorescence double staining
Tissues were fixed, embedded in paraffin and sectioned
as indicated above. Epitope retrieval was performed with
citrate buffer pH 6.0 (Zytomed). Primary antibodies
against CD3 (rabbit IgG1, DCS) and CD134 (mouse
IgG1, Becton Dickinson) were used and incubated for
60 minutes at room temperature simultaneously. Sec-
ondary antibodies conjugated to Cy2 and Cy3 (Dianova,
Hamburg) were applied for 30 minutes. Finally, the
slides were mounted with Immu Mount™ (Thermo
Fisher, Kehl, Germany).
Statistics
All values are expressed as mean ± SD. Significance for
the differences between groups was determined by the
Mann-Whitney U-test. Spearman’s rank correlation test
was applied for detecting correlations between different
study parameters. A P-value less than 0.05 was consid-
ered significant.
Results
Expression of CCR6 and phenotypic features of CCR6+
peripheral blood CD4+ cells
In order to characterise IL-17 producing cells with a
suitable marker expressed on the surface we analysed T
cells for the expression of CCR6 [20]. Peripheral blood
circulating CD4+CCR6+ cells were analysed in 28
patients and 11 healthy individuals. There were no dif-
ferences in the percentages of CD4+CCR6+ cells
between patients with SLE and healthy controls (19.74 ±
8.5% vs. 16.97 ± 5.6%, P = 0.34). Furthermore, there
were no significant differences between active (n = 10)
and inactive (n = 18) patients (18.63 ± 8.01% vs. 20.36 ±
9.04%, P = 0.46) or between patients with or without
lupus nephritis (22.39 ± 8.0% vs. 17.86 ± 8.08%, P =
0.24). There were also no differences in of CCR6 expres-
sion between patients with and without lupus nephritis
and healthy controls (22.39 ± 8.05% vs. 16.97 ± 5.67%
and 17.86 ± 8.08% vs. 16.97 ± 5.67%, P = 0.08 and P =
0.76, respectively). Active and inactive patients showed
no difference in levels of CCR6+ cells as compared to
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healthy controls (18.63 ± 8.01% vs. 16.97 ± 5.67% and
20.36 ± 9.04% vs. 16.97 ± 5.67%, P = 0.6 and P = 0.31,
respectively).
The CCR6+ subset was analysed for the expression of
costimulatory markers CD80 and CD134. Remarkably,
percentages of CD134 and CD80 expressing CCR6+ cells
were significantly increased in patients with SLE in com-
parison to healthy controls (CD134: 67.87 ± 12.23% vs.
59.27 ± 8.18%, P = 0.02; CD80: 26.46 ± 12.28% vs. 13.86
± 3.82%, P = 0.001).
Expression of costimulatory markers CD134 and CD80 on
CD4+CCR6+ cells in active and inactive patients and
patients with and without lupus nephritis
Patients with and without active disease, as assessed by
SLEDAI, and patients with and without lupus nephritis,
proven by renal biopsy, were analysed for CD80 expres-
sion on CD4+CCR6+ cells. The percentages of CD80
expressing on CD4+CCR6+ cells showed no difference
between active and inactive patients (23.58 ± 13.41% vs.
28.06 ± 11.07%, P = 0.37). There was a significant differ-
ence between inactive SLE patients and healthy controls
(28.06 ± 11.07% vs. 13.86 ± 3.82%, P = 0.0006). Expres-
sion of CD80 on CD4+CCR6+ cells in active patients
tended to be increased as compared to healthy controls
(23.58 ± 13.41% vs. 13.86 ± 3.82%, P = 0.062). Patients
with lupus nephritis showed significantly higher levels of
CD80 expression on CD4+CCR6+ cells in comparison to
healthy controls (22.13 ± 10.58% vs. 18.86 ± 3.82%, P =
0.02). The same applied for patients without lupus
nephritis (30.66 ± 12.75% vs. 18.86 ± 3.82%, P =
0.0009). Comparing patients with lupus nephritis and
patients without lupus nephritis no difference could be
observed (22.13 ± 10.58% vs. 30.66 ± 12.75%, P = 0.11).
Expression of CD134 on CD4+CCR6+ cells was signifi-
cantly higher in patients with inactive disease compared
to healthy controls (70.89 ± 10.35% vs. 59.27 ± 8.18%,
P = 0.0097) but not different from active patients (70.89
± 10.35% vs. 62.14 ± 14.16%, P = 0.17). Patients with
lupus nephritis expressed higher levels of CD134 on
peripheral blood CD4+ T-cells as compared to HC
(68.08 ± 7.52% vs. 59.27 ± 8.18%, P = 0.027). Patients
without lupus nephritis showed no difference in com-
parison to patients with lupus nephritis and healthy
individuals (67.75 ± 13.46% vs. 68.08 ± 7.52%, P = 0.91;
67.75 ± 13.46% vs. 59.27 ± 8.18%, P = 0.05).
SLE patients with active disease show increased levels of
IL-17 producing T-cells in peripheral blood
The percentage of IL-17 producing T-cells was analysed
in the peripheral blood of 30 SLE patients and 16
healthy controls. There was no significant difference
between SLE patients and healthy controls (1.17 ±
0.61% vs. 0.93 ± 0.30%; P = 0.37). Patients with active
disease had significantly elevated levels of IL-17 expres-
sing T-cells in the peripheral blood in comparison to
healthy controls (1.46 ± 0.58% vs. 0.93 ± 0.30%, P =
0.007). Active patients had also increased levels of IL17+
T-cells as compared to inactive patients (1.46 ± 0.58%
vs. 0.88 ± 0.5%, P = 0.002) (Figure 1). The expression of
IL-17 within CD8 cells revealed an expression of 0.9 ±
0.5% (n = 5).
Ex vivo IL-17 production of CD3+ cells correlates with
disease activity and is independent of renal involvement
The percentage of IL-17 producing CD3+ cells corre-
lated significantly with disease activity (P = 0.003, r =
0.53) (Figure 2). To study the influence of medication
we compared the proportion of IL-17 expressing cells in
patients on prednisone alone versus patients on a com-
bination of immunosuppressants. There was no differ-
ence between these groups. This observation could be
confirmed in a follow-up in 12 patients. Changes over
time (21 ± 13 weeks) of IL-17 expression were asso-
ciated with changes in disease activity (r = 0.81, P =
0.001). Expression of IL-17 in patients with lupus
nephritis (n = 13) was not different as compared to
patients without lupus nephritis (n = 14) (1.29 ± 0.65%
vs. 1.08 ± 0.57%, P = 0.34). A subanalysis revealed also
no difference regarding the the expression of IL-17
between patients with a class IV LN and patients with
class V (0.94 ± 0.53% vs. 1.62 ± 0.94%, P = 0.25). There
was also no association with other histological features.
Further, there was no correlation between expression of
IL-17 and anti-dsDNA titres or complement levels.
Patients with lupus nephritis showed no difference to
healthy controls (0.93 ± 0.30%, P = 0.15).
Phenotypic features of IL-17+ T-cells in patients with SLE
The expression of costimulatory markers CD80 and
CD134 was analysed within the IL-17+ subset in patients
and healthy controls. The percentages of CD134 and
CD80 expressing IL-17 producing T-cells were signifi-
cantly increased in SLE patients in comparison to
healthy controls (CD134: 71.78 ± 14.51% vs. 51.45 ±
16.58%, P = 0.002; CD80: 25.5 ± 14.99% vs. 14.99 ±
5.74%, P = 0.02) (Figure 3a, b). A subanalysis in SLE
patients (n = 5) showed that only 1.7 ± 1.8% IL-17 pro-
ducing T-cells were double positive for CD80 and
CD134. There was no significant correlation between
the proportion of CD134 and CD80 and IL-17 expres-
sion (P = 0.8 and P = 0.6, respectively).
Expression of costimulatory markers CD134 and CD80 on
IL17-producing T-cells in active and inactive patients and
patients with and without lupus nephritis
Patients with and without active disease were analysed
for CD80 expression on IL-17 producing T-cells. The
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percentages of CD80 expressing IL-17 producing T cells
showed no differences between active and inactive
patients (25.02 ± 16.01% vs. 25.97 ± 14.46%, P = 0.87).
There was a significant difference between inactive SLE
patients and healthy controls (25.97 ± 14.46% vs. 14.99
± 5.74%, P = 0.02). Expression of CD80 on IL-17 produ-
cing T cells in active patients tended to be increased as
compared to healthy controls (25.02 ± 16.01% vs. 14.99
± 5.74%, P = 0.07). Patients were further analysed based
on the presence of lupus nephritis. Patients with and
without lupus nephritis showed significantly higher
levels of CD80 expression on IL17+ cells as compared to
healthy controls (26.71 ± 15.85% and 26.90 ± 15.06% vs.
14.99 ± 5.74%, P = 0.04 and P = 0.02, respectively).
There was no difference in the expression of CD80 on
IL17+ cells between patients with and without lupus
nephritis (26.71 ± 15.85% vs. 26.90 ± 15.06%, P = 0.85)
(Figure 3c and 3d). No significant difference could be
observed comparing the expression of CD80 on IL-17
producing T-cells in patients with class IV and V lupus
nephritis (36.25 ± 18.66% vs. 21.93 ± 9.18%, P = 0.63).
Figure 1 IL-17 producing CD3+ T-cells in systemic lupus erythematosus. (a) Percentages of IL-17 producing CD3+ cells in patients with SLE
(n = 30) and healthy controls (HC) (n = 16). (b) A representative two colour immunofluorescence dot plot of CD3+ cells showing expression
levels of IL-17 from an SLE patient and a healthy control. Cells positive for both antibodies are represented in the right upper quadrant with the
percentage indicated. (c) Percentages of IL-17 producing CD3+ cells in active patients (n = 15), inactive patients (n = 15) and healthy controls (n
= 16). (d) Percentages of IL-17 producing CD3+ cells in patients with lupus nephritis (with LN) (n = 13), patients without lupus nephritis (without
LN) (n = 14) and healthy controls (n = 16). Data are presented as mean value. Significance was tested by the Mann-Whitney U-test. A P-value
less than 0.05 was considered significant.
Figure 2 Correlation of IL-17 producing CD3+ T-cells and
disease activity assessed by SLEDAI. Correlation between
percentages of IL-17 producing T cells for all samples taken (n = 30)
and disease activity as assessed by the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI). Spearman analysis
was performed to calculate the correlation. A P-value less than 0.05
was considered significant.
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Interestingly, there was a correlation between CD80
expression on IL-17 producing T-cells and anti-dsDNA
titres and decreased C3 levels, respectively (r = 0.6, P =
0.0003 and r = -0.5, P = 0.01).
Expression of CD134 on IL-17 producing T cells was
significantly higher in patients with active disease as
compared to healthy controls (74.87 ± 10.64% vs. 51.54
± 16.58%, P = 0.0009). Also in patients with inactive dis-
ease expression of CD134 on IL-17 producing T-cells
was higher as compared to healthy controls (68.69 ±
17.39% vs. 51.45 ± 16.58%, P = 0.0382), but it did not
differ from active patients (68.69 ± 17.39% vs. 74.87 ±
10.64%, P = 0.34). Patients with lupus nephritis
expressed higher levels of CD134 on peripheral T cells
as compared to healthy controls (72.69 ± 11.54% vs.
51.45 ± 16.58%, P = 0.0056). Patients without lupus
nephritis also showed higher levels of CD134 on IL-17
producing T cells in comparison to healthy individuals
(70.27 ± 17.18% vs. 51.45 ± 16.58%, P = 0.01). No differ-
ence could be observed between patients with and with-
out lupus nephritis (72.69 ± 11.54% vs.70.27 ± 17.18%,
P = 0.91) (Figure 3d). Further, expression of CD134 on
IL-17 producing T-cells showed no significant differ-
ences between class IV and V lupus nephritis (69.05 ±
10.97% vs. 78.27 ± 6.51%, P = 0.23).
Immunohistochemistry (IHC) staining for CD134 in
inflamed tissue
To determine whether CD134+ T-cells were present in
inflammed organs of SLE patients, four renal biopsies
were stained for CD134 and CD3. CD134+ cells were
located within or in the neighbourhood of small vessels
and tubulointerstitial lymphocyte infiltrates. Single cells
were found around glomeruli. Serial sections revealed a
Figure 3 Expression of costimulatory markers CD80 and CD134 on IL-17+ CD3+ cells in SLE. (a) Percentages of CD80+ IL-17 producing
CD3+ cells in patients with SLE (n = 30) and healthy controls (HC) (n = 13). (b) The expression of CD134+ on IL-17 producing CD3+ cells from
patients with SLE (n = 30) and healthy controls (HC) (n = 13). (c) Percentages of CD80+ and CD 134+ IL-17 producing T cells form active (n = 15)
and inactive (n = 15) patients with SLE and healthy controls (n = 13). (d) Expression of CD80+ and CD 134+ on IL-17 producing T cells from
patients with lupus nephritis (with LN) (n = 13), patients without lupus nephritis (without LN) (n = 14) and healthy controls (n = 13). Data are
shown as mean value. Significance was tested by the Mann-Whitney U-test. A P-value less than 0.05 was considered significant.
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colocalization with CD3+ T-cells; this could be con-
firmed by immunofluorescent double staining with CD3
and CD134 (Figure 4).
Discussion
The results of this study suggest that IL-17 producing
cells play a pivotal role in the pathogenesis of systemic
lupus erythematosus. In vitro stimulated CD3+ cells
from active SLE patients produced significantly higher
levels of IL-17 as compared to healthy controls. Remark-
ably, only T cells isolated from active patients produced
higher levels of IL-17 than controls. The association
between IL-17 production and disease activity was
further supported by a significant correlation of IL-17
expression and disease activity as assessed by SLEDAI.
These findings are in accordance with a large previous
study by Yang et al. in which 50 patients were enrolled
[14]. In addition, Wong et al. demonstrated increased
circulating plasma concentrations of IL-17 in SLE
patients as compared to healthy controls. In contrast to
our study a correlation of plasma levels of IL-17 and
disease activity could only be found in patients without
renal disease [29]. Both studies lack a detailed subanaly-
sis of patients with and without lupus nephritis. There-
fore, a subanalysis was performed on the presence of
lupus nephritis in this study. Patients with biopsy pro-
ven lupus nephritis were compared to patients without
renal involvement. However, a significant difference in
the amount of IL17-producing peripheral CD3+ cells
could not be found between these groups which could
be related to the rather small size and heterogeneous
composition of this group of biopsy proven lupus
nephritis patients. Moreover, the impact of immunosup-
pressive drugs remains uncertain although we found no
difference in patients on prednisone versus patients with
a combination of immunosuppressive drugs regarding
either IL-17 expression or expression of costimulatory
molecules (data not shown). There is growing evidence
in murine models that IL-17 plays a crucial role in the
pathogenesis of renal diseases such as lupus nephritis
[16,17]. These results can be explained by the hypotheti-
cal migration of IL-17 cells into inflamed kidneys.
The present study reveals that IL-17 cells express sig-
nificantly higher amounts of the costimulatory markers
CD80 and CD134. Ex vivo stimulation has been shown
to upregulate the expression of CD134 over time but
the significant difference between active patients and
controls seem to be associated with disease activity
according to our findings [30]. In addition, we detected
CD134+ T-cells in lupus nephritis biopsies. These find-
ings have been confirmed by Zhou et al. in a larger ana-
lysis 40 kidney biopsies [31]. Possibly, in humans these
CD134+ T-cells infiltrate the kidney after ligation with
CD134L expressed by endothelial cells which could sub-
sequently lead to IL-17 mediated renal injury. Blocking
CD134/CD134Ligand interaction as a therapeutic inter-
vention has been successfully used in lupus mice [30].
However, the role of IL-17 has not been investigated in
that study. Interestingly, a recent report investigating
the influence of CD134/CD134Ligand interaction on IL-
17 cytokine production suggests that IL-17 production
is downregulated after ligation of CD134 [32]. This
could be interpreted as a negative feedback loop for the
effector function of CD134+ cells but the detailed
mechanisms remain unclear. An important regulatory
role of Th17 cells through the CD28/CD80 pathway was
also discussed in a murine model [33].
Taken together we demonstrated that IL-17 producing
cells are closely linked to disease activity in SLE patients
and express high levels of the costimulatory markers
Figure 4 Kidney CD134+ CD3+ infiltrating T-cells in lupus nephritis. (a) Representative renal biopsy of an SLE patient with lupus nephritis
(WHO class IV). The biopsy was stained for CD134 using immunohistochemistry. (b) Staining of the biopsy for CD3+ and CD134+ cells by
immunofluorescence. CD3 (A), CD3/DAPI (B), CD134 (C) and colocalization of CD134 with CD3 (D).
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CD80 and CD134. These new subsets of IL-17 cells
might be important in human lupus nephritis.
Conclusions
The presence of CD134+ T-cells in renal biopsies of
lupus nephritis patients suggest that these cells migrate
to the kidney and might contribute to inflammatory
processes through IL-17 secretion. Further studies are
necessary to dissect pathogenic role of IL-17 in lupus in
order to establish IL-17 as a therapeutic target in SLE.
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